Skip to content
BillRazor
Generic J1740

IBANDRONATE 3 MG/3 ML SYRINGE

IBANDRONATE 3 MG/3 ML SYRINGE, a generic medication with a $53.32 acquisition cost, typically shows significant pricing variations between acquisition cost and hospital billing rates.

By Priya Iyengar , Senior Billing Analyst · ·
Data from CMS files published FY 2024 CMS IPPS. Refreshed weekly.
About the analyst

Priya Iyengar leads the billing code review team at BillRazor Research. She analyzes NCCI bundling edits, DRG coding, and regional rate variation. Expertise: NCCI bundling, DRG analysis, regional pricing.

NADAC acquisition cost data
CMS drug pricing benchmarks
Updated 2026-04-03
Drug acquisition cost — IBANDRONATE 3 MG/3 ML SYRINGE
NADAC cost$53.32 per unit
Hospital charges for this drug vary — typically 3–8x the acquisition cost. No observed hospital charge data is available for this specific drug.
$53.32
NADAC acquisition cost
INJECTABLE
Dosage form
INTRAVENOUS
Route

Ibandronate 3 mg injection treats osteoporosis and is typically administered quarterly in outpatient or hospital settings. This injectable formulation often carries higher facility fees compared to oral bisphosphonate alternatives, with reimbursement varying significantly between administration sites.

Check your bill amount
Enter the charge for IBANDRONATE 3 MG/3 ML SYRINGE from your bill to compare against the NADAC acquisition cost.
$

No credit card required. Results in 60 seconds.

Research suggests 49–80% of hospital bills contain errors. Our system checks every line item against Medicare benchmarks.
Rates shown are from the 2026 Medicare Physician Fee Schedule and CMS IPPS. BillRazor compares your bill against these data sources. See how it works →

Data source: National Average Drug Acquisition Cost (NADAC) survey, published by CMS. HCPCS drug pricing codes from Medicare Part B Drug Average Sales Price file.

What NADAC means: The average price pharmacies pay to acquire this drug from wholesalers. Hospital charges for the same drug are typically higher due to facility fees, compounding, and administration costs.

Limitations: NADAC reflects pharmacy acquisition cost, not patient out-of-pocket cost. Insurance copays, formulary tiers, and manufacturer rebates affect what patients actually pay.

Upload your bill — free instant analysis